Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

This phase II trial studies how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery (unresectable). Binimetinib and imatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and imatinib may help treat patients with KIT-mutant melanoma.

NCT Number	NCT04598009
Lead Sponsor	University of California, San Francisco Collaborators: Array BioPharma
Conditions	Melanoma Stage III, Melanoma Stage IV
Enrollment	25 participants
Start Date	2021-03-03
Primary Completion	2027-05-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-04